Open AccessPlacebo‐Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV‐1 Infection
Author(s) -
Neil M. Flynn,
Donald N. Forthal,
Clayton Harro,
Franklyn N. Judson,
Kenneth H. Mayer,
Michael F. Para
Publication year - 2005
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/428404
Subject(s) - seroconversion , placebo , medicine , vaccine trial , recombinant dna , human immunodeficiency virus (hiv) , clinical endpoint , lentivirus , immunology , virology , clinical trial , transmission (telecommunications) , viral disease , biology , pathology , alternative medicine , biochemistry , electrical engineering , gene , engineering
A vaccine is needed to prevent human immunodeficiency virus type 1 (HIV-1) infection.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom